Pretoria, 21 April 2023 - The South African Health Products Regulatory Authority (SAHPRA) issued media statements on 4 August 2022 and 12September 2022, relating to two fatal cases of Guillain-Barré syndrome (GBS) following vaccination with COVID-19 Vaccine Janssen. SAHPRA has been informed of a third...
Pretoria, 12 September 2022 - On the 04th of August 2022, SAHPRA issued a media statement relating to the first fatal case of GBS following vaccination with COVID-19 Vaccine Janssen. Recently, SAHPRA has been informed of a second fatal case of Guillain-Barré syndrome (GBS) following...
04 August 2022 On 31 March 2021, SAHPRA approved the use of the COVID-19 Vaccine Janssen for individuals 18 years of age and older as a single primary vaccination dose. COVID-19 Vaccine Janssen was later approved as a single booster dose given at least two months...
